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Segmental neuroﬁbromatosis type 1 (SNF1), characterized by the regionally limited distribution of neuroﬁbromatosis
type 1 (NF1) features, has been attributed to mosaicism for an NF1 gene mutation. The occurrence of classical NF1 in
the offspring of a parent with SNF1 suggests that cutaneous mosaicism may be accompanied by gonadal mosaicism.
We studied a girl with generalized NF1, and her mother who has SNF1. A recurrent nonsense mutation in exon 31
(R1947X) of the NF1 gene was identiﬁed in the lymphocyte DNA of the affected child by denaturing high-performance
liquid chromatography and PCR/direct sequencing. DNA sequence analysis failed, however, to identify the R1947X
mutation in peripheral lymphocytes, and in keratinocytes and ﬁbroblasts cultured from affected and unaffected skin
in the mother. DNA fragments containing exon 31 were then cloned from each cell line and these clones were
screened using allele-specific PCR. The R1947X mutation was identiﬁed in 29 of 146 clones derived from keratin-
ocytes from the affected region and in 12 of 136 clones derived from ﬁbroblasts from the affected region, but in no
clones derived from clinically unaffected tissues. These ﬁndings conﬁrm that gonosomal mosaicism can occur in
SNF1, with consequent important implications for genetic counselling.
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Neurofibromatosis type 1 (NF1) is an autosomal dominant
disorder that affects about 1 in 3000 individuals worldwide.
The mutation rate for the NF1 gene is  5  104, almost
10-fold higher than observed for most other inherited dis-
ease genes. As a consequence, one half of all NF1 patients
result from new mutations of the NF1 gene.
Segmental neurofibromatosis type 1 (SNF1) is charac-
terized by the regionally limited distribution of the features
of NF1. First described by Gammel (1931), SNF1 was sub-
sequently termed ‘‘sectorial neurofibromatosis’’ by Crowe
et al (1956), who suggested somatic mosaicism for NF1 as
the cause. SNF1 was later defined clinically by Riccardi
(1982) as a form of neurofibromatosis in which the path-
ognomonic neurofibromas and cafe´-au-lait spots (with or
without freckling) are confined to one region of the body.
The pertinent features of this condition were summarized by
Viskochil and Carey (1994) and comprehensively reviewed
by Ruggieri and Huson (2001).
SNF1 is not infrequent (approximately 1 in 40,000 or
0.0025% of the general population) (Ruggieri and Huson,
2001) and the clinical phenotype is variable. Some patients
display only pigmentary changes, others only neurofibro-
mas, whereas some manifest both. SNF1 usually involves
only one body segment. Alternatively, some patients exhibit
bilateral symmetrical or assymetrical involvement of body
regions. As yet, however, no large-scale systematic genetic
and clinical study of SNF1 has been performed.
Although SNF1 is usually sporadic, there are several re-
ports of NF1 families in which a parent with SNF1 has a
child with generalized NF1 (Uhlin, 1980; Rubenstein et al,
1983; Boltshauser et al, 1989; Moss and Green, 1994).
These reports support the idea that SNF1 results from so-
matic mosaicism for an NF1 gene mutation, affecting pa-
rental gametes as well as the skin (Moss and Green, 1994).
The rare occurrence of SNF1 in two generations of the same
family is, however, more difficult to explain (Rubenstein et al,
1983; Ruggieri and Huson, 2001).
Recently, fluorescent in situ hybridization (FISH) was
used to identify a heterozygous deletion of the entire NF1
gene in about 18% of fibroblasts cultured from a cafe´-au-lait
spot from the affected region of a patient with SNF1 (Tinsc-
hert et al, 2000). This gross gene deletion was, however,
absent both from peripheral leukocytes and from fibroblasts
derived from non-affected regions of the patient’s body. This
finding supports the idea that (i) SNF1 is because of NF1
gene mutation and (ii) that the affected individual was a so-
matic mosaic. Further studies are now required both to
confirm these initial results and to elucidate the mutational
spectrum and tissue-type distribution of the somatic mo-
saicism associated with SNF1, particularly where gonadal
mosaicism is also suspected. To this end, we describe here
the molecular genetic analysis of a family with NF1/SNF1.
Abbreviations: NF1, neurofibromatosis type 1; SNF1, segmental
neurofibromatosis type 1
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Results
A nonsense mutation in exon 31 of the NF1 gene (R1947X)
was found in lymphocyte genomic DNA from the affected
child by denaturing high-performance liquid chromatogra-
phy (dHPLC) followed by DNA sequencing (Fig 1A,C) but it
was not present in the mother’s lymphocytes. Initial PCR
direct sequencing of exon 31, however, failed to identify the
R1947X mutation in DNA derived from the affected skin
of the mother. The R1947X mutation was nevertheless
identified in 29 of 146 clones derived from maternal kera-
tinocytes cultured from the affected region and in 12 of 136
clones from maternal fibroblasts derived from the affected
region using allele-specific PCR (Fig 1B). This mutation was
not detected by either technique in DNA derived from un-
affected maternal fibroblasts and keratinocytes.
Discussion
Somatic mosaicism results from mutations occurring during
mitotic cell divisions in the embryo with subsequent clonal
expansion of the affected cells. The clinical effect of so-
matic mosaicism depends critically upon the developmental
stage at which the mutation occurs. A mutation that occurs
very early on in embryonic development is likely to affect
many somatic tissues and may therefore be expected to
result in generalized NF1 (Colman et al, 1996). By contrast,
mutations occurring later on may give rise to a phenotype
confined to a single body region or even to a single organ
(Tinschert et al, 2000; Petek et al, 2003; Vandenbroucke
et al, 2004). Somatic mosaicism arising at a very early em-
bryonic stage can involve both somatic cells and germ cells.
Such individuals (gonosomal mosaics) are at risk of having
affected children.
The natural history and progression of the cutaneous
changes of SNF1 are similar to generalized NF1. In both
conditions, pigmentary changes and plexiform neurofibro-
mas usually appear in childhood, whereas neurofibromas
usually develop during adolescence. As many SNF1 pa-
tients are asymptomatic with minimal clinical signs, the
condition may go unrecognized even by the patient (Ingordo
et al, 1995) and hence is almost certainly underdiagnosed.
Although SNF1 is commonly seen in pediatric NF1 referral
centers (Listernick et al, 2003), there are no clear-cut rec-
ommendations for its clinical management. Furthermore,
there are currently no clinical or molecular means to ascer-
tain whether a patient with localized freckles or cafe´-au-lait
macules has (a) skin markings not caused by NF1 gene
mutations; (b) SNF1 affecting the skin but not the gonads; or
(c) gonosomal mosaicism for NF1 with a risk of transmitting
the full-blown disorder.
Figure1
Somatic MOSAICISM in the NF1 gene. (A) Denaturing high-perform-
ance liquid chromatography profiles of an exon 31-containing fragment
derived from the NF1 gene from the affected child and segmental ne-
urofibromatosis mother. A second lower-mobility peak is evident in the
child’s lymphocyte DNA sample but not in DNA derived from the moth-
er’s keratinocytes or fibroblasts. (B) Allele-specific primers correspond-
ing to mutant and wild-type alleles for exon 31 were designed to
differentiate between the ‘‘C-containing’’ (wild-type) product and the
‘‘T-containing’’ (mutant) product. Both primer pairs amplify an exon 31-
specific fragment of 184 bp, and the cloned PCR products were re-
solved on a 2% agarose gel. 2210 and 2209 represent samples of
cloned DNA from keratinocytes derived from skin biopsies taken from
the affected (2210) and unaffected (2209) regions. Similarly, 2212 and
2211 constitute cloned DNA from fibroblasts derived from skin biopsies
from affected (2212) and unaffected (2211) body regions. 631 corre-
sponds to cloned DNA from the lymphocytes of the affected child. The
184 bp PCR product in lanes 1, 7, 9, 11, 13, and 15 represents the
amplified wild-type allele, whereas PCR products in lanes 4, 6, and 14
correspond to the mutant allele. PCR products corresponding to both
wild-type and mutant NF1 alleles were present in cloned material from
maternal affected cells (2210 and 2212) and from the child (631), but
only the wild-type PCR product was evident in DNA from normal ma-
ternal cells (2209 and 2211). Ma, 25 bp marker; Kerat, keratinocytes;
Fibr, fibroblasts; B, blank; Aff, affected; Un, unaffected; Lympho,
lymphocytes; W, wild-type; M, mutant. (C) 631: DNA sequence analysis
of exon 31 fragment derived from mother and child. A heterozygous
5839C4T transition (R1947X) identified in exon 31 of the child’s NF1
gene. 2210/2212: same mutation identified in cloned PCR fragments
from DNA derived from maternal affected keratinocytes and fibroblasts.
2209/2211: wild-type NF1 exon 31 sequence in cloned PCR fragment
derived from unaffected maternal keratinocyte and fibroblast DNA.
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The identification of NF1 gene mutations in children with
classical NF1, one of whose parents has identifiable SNF1,
should provide the means to investigate the tissue distri-
bution of the parental NF1 mutation. Our study has dem-
onstrated gonosomal mosaicism in an SNF1 patient at the
molecular level. Using DNA cloning and allele-specific PCR,
and using biopsies obtained from both the affected and
unaffected regions, variable levels of mosaicism for the
identified mutation were apparent in the different cell line-
ages (keratinocytes and fibroblasts) in the SNF1 parent,
whereas the child with generalized NF1 possessed the
(heterozygous) mutation in her lymphocyte DNA at a level
readily detectable by PCR/direct sequencing.
Segmental or ‘‘localized disease’’ has been mainly stud-
ied in dermatological disorders in which the pattern of af-
fected and healthy skin follows the ‘‘lines of Blaschko’’. One
of us (Moss, 1999) postulated that disorders exhibiting
Blaschko’s lines (Moss et al, 1993) are because of mutations
in genes expressed in epidermal cells (keratinocytes and
melanocytes) rather than in dermal fibroblasts. This is sup-
ported by preliminary data on SNF1 collected by Huson and
Ruggieri (2000), that have suggested that pigmentary
changes alone tend to follow Blaschko’s lines whereas
neurofibromas tend to have a dermatomal distribution. Muta-
tions in the ATP2A2 gene have been identified in the af-
fected but not the unaffected skin or leukocytes of seg-
mental Darier’s disease patients (Sakuntabhai et al, 2000). A
mutation in the KRT10 gene has been identified in keratin-
ocytes from a linear bullous congenital ichthyosiform
erythroderma (BCIE) patient but not in the normal epidermis
(Moss et al, 1995). Three families with apparent gonosomal
mosaicism for BCIE have also been described, in which a
parent with linear BCIE had offspring with generalized BCIE
caused by keratin gene (KRT1 and KRT2) mutations also
present in the parents’ abnormal skin (epidermal cells: ker-
atinocytes and melanocytes) but not in the normal skin
(Paller et al, 1994).
Our patient with SNF1 is presumed to be a gonosomal
mosaic who expresses the mutant NF1 allele in at least
some of her germline cells as well as in a variable proportion
of her somatic cells. Notably, in our study, DNA analysis
from cultured fibroblasts and keratinocytes derived from the
affected region failed to identify an NF1 mutation, whereas
DNA cloning combined with allele-specific PCR facilitated
the identification of mosaicism. Similarly, Schultz et al (2002)
were unable to detect any NF1 mutations in fibroblasts cul-
tured from neurofibromas from an SNF1 patient. These
findings suggest that DNA analysis of cultured cells may not
be the optimal approach to seek evidence for mosaicism.
Identification of NF1 gene mutations in SNF1 patients will
facilitate both the clinical management and genetic coun-
selling of these individuals (Listernick et al, 2003). Genetic
counselling in NF1 is difficult because gonadal mosaicism
for NF1 has been reported in a clinically normal father (La-
zaro et al, 1994) and SNF1 patients have had offspring with
either classical or SNF1 (Rubenstein et al, 1983; Boltsha-
user et al, 1989; Moss and Green, 1994; Huson and Rug-
gieri, 2000). Knowing the mutation in an SNF1 parent at
least makes it possible to exclude or confirm generalized
NF1 in the offspring by first trimester prenatal diagnosis.
Interestingly, the nonsense mutation R1947X identified in
this family is a recurrent mutation (Upadhyaya and Cooper,
1998).
Our study has, however, demonstrated that the cell lin-
eage as well as the method of analysis are critical to ob-
taining a meaningful diagnostic result. Tinschert et al (2000)
identified mutations in only 15% of fibroblasts in their study
of SNF1. In our study, the mutation was detected in 9% of
fibroblast clones derived from the affected skin. We found a
higher proportion (20%) of affected keratinocyte clones, in
keeping with the epidermal origin of cafe´-au-lait-macules.
The frequencies of mutant clones observed in our study,
however, may not accurately reflect the percentage of mo-
saicism in the two cell lineages. Unfortunately, we were un-
able to culture and study melanocytes, which would have
been the most relevant cell type to study. We speculate that
the original embryonic mutation was transmitted to all skin
cell types within a limited region. Subsequent embryonic
migration of the daughter cells led to some scattering. Bi-
opsy from a site defined by the melanocyte abnormality
would be expected to exhibit the mutation in most me-
lanocytes and many keratinocytes but in a smaller propor-
tion of fibroblasts. Biopsy from adjacent clinically normal
skin might pick up a few mutant fibroblasts and keratin-
ocytes. Biopsy from a clinically normal skin site remote from
the lesion, however, would be unlikely to pick up any mutant
cells.
These data should not only potentiate molecular diag-
nostic testing and improve our understanding of the mo-
lecular mechanisms underlying SNF1/NF1 but also promise
to facilitate genetic counselling in individuals with SNF1 re-
garding the risk of NF1 in their offspring. With the availability
of more sensitive quantitative assays capable of detecting
low-frequency mosaic mutations against normal back-
grounds, it will become possible to elucidate the molecu-
lar basis of the pathology in the majority of NF1/SNF1
families, and to offer antenatal testing if required.
Materials and Methods
Clinical materials Molecular genetic analysis was performed on
a previously described NF1/SNF1 family (Moss and Green, 1994).
Adherance to Helsinki guidelines as well as written consent was
obtained from this family. An ethical approval was also obtained for
this study. The daughter had classical NF1 with generalized cafe´-
au-lait macules, axillary freckling, and a large plexiform neurofi-
broma under the jaw. The mother had an area of freckling and cafe´-
au-lait macules confined to the left upper quadrant, with ipsilateral
axillary freckling and Lisch nodules in one eye. Blood samples
were obtained from the fully affected daughter and the segmentally
affected mother. Maternal skin biopsies from both a cafe´-au-lait
macule and an unaffected region were obtained under local an-
esthetic, and the cells were cultured. DNA was extracted from
peripheral lymphocytes, fibroblasts, and keratinocytes from the
affected and unaffected skin regions.
dHPLC and DNA sequence analysis All 60 exons of the NF1 gene
were amplified by PCR and each exon was screened for mutations
using dHPLC (Upadhyaya et al, 2004). Those PCR products
exhibiting a heterozygous pattern were purified and directly se-
quenced using an ABI Prism 3100 Genetic Analyzer (PE Applied
Biosystems, Foster City, California).
Cloning Specific PCR products obtained from fibroblasts and ker-
atinocytes were cloned into the pGEM-T easy vector before being
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transformed into Escherichia coli DH5a-competent cells. Ligation
was performed in 10 mL containing 1 mL vector, 3 mL PCR insert,
1 mL T4 DNA ligase (10 U), and 5 mL 2  buffer. The reaction was
incubated at 101C overnight before being stored at 201C.
PCR from bacterial colonies Colonies for mutation analysis were
picked and PCR amplified using pGEM-T easy vector primers
to allow identification of inserts prior to allele-specific PCR and
sequencing. PCR was set up in microtiter plates containing 40 mL
volumes and one single colony picked from an LB ampicillin plate.
The PCR cycling parameters used were as follows: (941C  3 min),
35 cycles (941C  30 s)(581C  30 s)(721C  1 min), and (721C 
10 min). Primer sequences were specific to the pGEM-T easy vec-
tor and comprised pGEM-T F 50-GCCCGACGTCGCATGCTC-30
and pGEM-T R 50-TCCCATATGGTCGACCTGC-30.
Allele-specific PCR PCR was setup in microtiter plates containing
40 mL volumes and a single colony picked from an LB ampicillin
plate. The PCR master mix comprised 4 mL 10  primers (5 pm
per mL), 4 mL 10  buffer (15 mM MgCl2), 6.4 mL dNTP (5 mM), 0.25
mL Taq DNA polymerase (5 U per mL), and 22.4 dH2O. PCR cycling
parameters used were as follows: denaturation at (941C for 5 min),
25 cycles of (941C  30 s)(601C  30 s)(721C  30 s), and
(721C  10 min). For analysis of exon 31 allelic variants, two for-
ward primers were designed, with the 30 base of each primer
matching only one of the biallelic single nucleotide polymorphism
(SNP) bases to be evaluated. Incorporation of a primer mismatch
at the third base from the 30 end of the primer has been shown to
enhance the specificity of the PCR by further destabilizing the
extension of the doubly mismatched primer. A common reverse
primer was used.
Forward primer sequences were as follows:
Ex31-WT F 50-GCAAGCATAATGATGATGCCACAC-30
Ex31-MUT F 50-GCAAGCATAATGATGATGCCACAT-30
The common reverse primer sequence was as follows:
Ex31 R 50-CAGATAAATATGTGCACAAAGGAGA
Both primer pairs amplified an exon 31-specific fragment of
184 bp.
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